
Vaxcyte (PCVX) Stock Forecast & Price Target
Vaxcyte (PCVX) Analyst Ratings
Bulls say
Vaxcyte Inc. is positioned favorably within the biopharmaceutical sector, particularly due to the impressive immunogenic response demonstrated by its product candidates VAX-24 and VAX-31, which have outperformed existing competitors such as Prevnar 20 in adult studies. The company shows a strong potential for leadership in the next-generation pneumococcal vaccine market, backed by high expectations for robust seroresponse rates in infants and substantial projected global revenue opportunities of $7-10 billion. Despite the potential for risks in U.S. vaccine policies, Vaxcyte’s advancing clinical data presents a compelling case for long-term investment, suggesting a significant upside potential for its shares over the next few years.
Bears say
The financial outlook for Vaxcyte Inc appears negative due to several critical risks that could hinder its growth and profitability. The company faces potential delays in research and development, regulatory approvals, and commercial uptake, all of which could significantly impact investor confidence and stock performance. Furthermore, if Vaxcyte's vaccine candidates fail to demonstrate safety and efficacy in clinical trials or if competitors advance faster, the company's ability to capture market share and generate projected revenues could be severely limited, leading to a pessimistic market sentiment.
This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.
Vaxcyte (PCVX) Analyst Forecast & Price Prediction
Start investing in Vaxcyte (PCVX)
Order type
Buy in
Order amount
Est. shares
0 shares